CytomX Therapeutics (STU:6C1) EV-to-Revenue : -0.35 (As of Jan. 18, 2025)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CytomX Therapeutics's enterprise value is €-40.0 Mil. CytomX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €116.0 Mil. Therefore, CytomX Therapeutics's EV-to-Revenue for today is -0.35.

The historical rank and industry rank for CytomX Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:6C1' s EV-to-Revenue Range Over the Past 10 Years
Min: -4.57 Med: 1.82 Max: 93.95
Current: -0.33

During the past 11 years, the highest EV-to-Revenue of CytomX Therapeutics was 93.95. The lowest was -4.57. And the median was 1.82.

STU:6C1's EV-to-Revenue is ranked better than
91.64% of 1041 companies
in the Biotechnology industry
Industry Median: 7.11 vs STU:6C1: -0.33

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-01-18), CytomX Therapeutics's stock price is €0.81. CytomX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €1.39. Therefore, CytomX Therapeutics's PS Ratio for today is 0.58.

CytomX Therapeutics EV-to-Revenue Historical Data

The historical data trend for CytomX Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics EV-to-Revenue Chart

CytomX Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.08

0.36

-0.01

-1.31

-0.56

CytomX Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-Revenue	Get a 7-Day Free Trial															-0.98	-0.56	0.09	-0.25	-0.12

Competitive Comparison of CytomX Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, CytomX Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's EV-to-Revenue falls into.

CytomX Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CytomX Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	-40.047	/	115.999
	=	-0.35

CytomX Therapeutics's current Enterprise Value is €-40.0 Mil.
CytomX Therapeutics's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €116.0 Mil.

CytomX Therapeutics (STU:6C1) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CytomX Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.81	/	1.39
	=	0.58

CytomX Therapeutics's share price for today is €0.81.
CytomX Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.39.

CytomX Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines